Clinical Daily Summary: What Happened on October 13, 2026

Obuprazine improved schizophrenia symptom scores versus placebo

Tortugas Neuroscience and Hansoh Pharma said obuprazine met the primary endpoint in a randomized, double-blind Phase 2b study of adults with acute schizophrenia.1 At day 42, the lowest-dose group’s average Positive and Negative Syndrome Scale (PANSS) score fell 28.6 points, compared with 11.9 points on placebo.1 The placebo-adjusted differences were 16.7, 13.2 and 14.7 points for the low, middle and high doses, respectively.1

At day 42, all three doses also improved positive and negative symptom scores and a cognitive measure versus placebo.1 The companies said obuprazine’s results were numerically better than aripiprazole’s on several measures, including the primary endpoint.1 Tortugas plans to file a US investigational new drug application and submit the full results to a peer-reviewed journal.1

Also worth knowing

• 

  In the Phase 1 portion of the CARMA trial, eight of 12 patients treated with ELC-301 had complete metabolic responses, Elicera Therapeutics said. Six remained in response at their latest assessment, and no dose-limiting toxicities were reported across three dose groups.3

• P

  Tridem Bioscience enrolled the first patients in a Phase 1b trial assessing the safety and immune response to its Parkinson’s vaccine candidate TRB-001. The company expects top-line results in mid-2027.4

• N

  A secondary analysis found that patients’ own HIV antibodies and infused antibodies both helped delay viral rebound after antiretroviral therapy was paused.5

• 

  Ambry Genetics introduced GenomeNext, a whole-genome diagnostic test that uses a human pangenome reference, offers optional RNA analysis and includes ongoing case reanalysis.6

Also published

• Females with autoimmune disease 'less likely to be believed' pharmaphorum
• Human–artificial intelligence collaboration for comanaging epilepsy in real time Nature Medicine
• Proteomic aging clocks go to trial Nature Biotechnology